Pharmacokinomic Profiling Using Patient-Derived Cell Lines Predicts Sensitivity to Imatinib in Dermatofibrosarcoma Protuberans
Cells · 2025
DOI: 10.3390/cells14120884 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cells, 2025. Verfasst von Rei Noguchi und 6 weiteren Autor:innen. Beteiligte Einrichtung: Division of Rare Cancer Research, National Cancer Center Research Institute, 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045, Japan. Hauptthemen laut MEDLINE: Imatinib Mesylate, Dermatofibrosarcoma, Antineoplastic Agents, Skin Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: JSPS KAKENHI.
Abstract (Originalsprache)
Dermatofibrosarcoma protuberans (DFSP) is a rare sarcoma, characterized by a COL1A1-PDGFB fusion. Imatinib, a multi-target tyrosine kinase inhibitor, is a standard treatment of DFSP. However, resistance emerges in 10–50% of cases. There is an urgent need for predictive biomarkers to refine the patient selection and improve therapeutic outcomes. We aimed to identify predictive biomarkers for imatinib response and explored a pharmacokinomic approach using in vitro assays with patient-derived DFSP cell lines. Four DFSP cell lines that we established were analyzed for tyrosine kinase activities on PamChip, a three-dimensional peptide array, in the presence and absence of imatinib, along with an imatinib-sensitive cell line, GIST-T1, as a positive control. Drug screening was also performed using 60 FDA-approved tyrosine kinase inhibitors, including imatinib. The kinomic profiles were compared with the kinase inhibitor screening results to identify predictive druggable targets. Drug sensitivity was associated with increased activity of PDGFRB, as indicated by the PamChip assay and Western blotting. Furthermore, imatinib sensitivity correlated with the activity of three kinases: FER, ITK, and VEGFR1, suggesting their potential as potential predictive biomarkers. Our cell-based pharmacokinomic approach using patient-derived DFSP cell lines would facilitate the identification of resistant cases to imatinib and guide alternative therapeutic strategies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Rare Cancer Research, National Cancer Center Research Institute, 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045, Japan.
- Department of Oncopeptidomics, Tochigi Cancer Center, 4-9-13 Yohnan, Utsunomiya 320-0834, Japan.
- Department of Peptidomics, Sasaki Institute, 2-2 Kanda-Surugadai, Chiyoda-ku, Tokyo 101-0062, Japan.
- Department of Proteomics, National Cancer Center Research Institute, 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045, Japan.
- Department of Musculoskeletal Oncology and Rehabilitation Medicine, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045, Japan.
- Department of Patient-Derived Cancer Model, Tochigi Cancer Center, 4-9-13 Yohnan, Utsunomiya 320-0834, Japan.
ORCID-Profile: Rei Noguchi, Mari Masuda, Akira Kawai, Yuki Yoshimatsu, Tadashi Kondo
Förderung
- JSPS KAKENHI
Zitieren
APA
Noguchi, R., Ono, T., Sasaki, K., Masuda, M., Kawai, A., Yoshimatsu, Y., & Kondo, T. (2025). Pharmacokinomic Profiling Using Patient-Derived Cell Lines Predicts Sensitivity to Imatinib in Dermatofibrosarcoma Protuberans. Cells. https://doi.org/10.3390/cells14120884
Vancouver
Noguchi R, Ono T, Sasaki K, Masuda M, Kawai A, Yoshimatsu Y, et al. Pharmacokinomic Profiling Using Patient-Derived Cell Lines Predicts Sensitivity to Imatinib in Dermatofibrosarcoma Protuberans. Cells. 2025. doi:10.3390/cells14120884
BibTeX
@article{Noguchi2025,
author = {Noguchi, Rei and Ono, Takuya and Sasaki, Kazuki and Masuda, Mari and Kawai, Akira and Yoshimatsu, Yuki and Kondo, Tadashi},
title = {Pharmacokinomic Profiling Using Patient-Derived Cell Lines Predicts Sensitivity to Imatinib in Dermatofibrosarcoma Protuberans},
journal = {Cells},
year = {2025},
doi = {10.3390/cells14120884}
}
EUVIMED